The data include new Phase 3 AFFIRM findings for SKYRIZI (risankizumab-rzaa) in advanced therapy-naïve Crohn's disease (CD) patients, as well as open-label extension analyses demonstrating long-term ...
ABBV's Skyrizi and Rinvoq are expected to drive Q3 growth, offset Humira's ongoing decline and face rising competition in the ...
New Phase 3 AFFIRM data show higher rates of clinical and endoscopic response in Crohn's disease patients treated with subcutaneous SKYRIZI versus placebo across all efficacy endpoints ...
The recommendations surround important updates to standard criteria that are commonly used despite being decades old.
Johnson & Johnson (NYSE: JNJ) today announced new three-year data from the Phase 3 GALAXI 2 and 3 studies showing durable ...
Around it, AbbVie ABBV+1.49% also presented analyses of Skyrizi's open-label extension showing sustained endoscopic outcomes ...
Johnson & Johnson (NYSE: JNJ) today announced new Phase 3 data showing consistent combined fistula remission outcomes with ...
TORONTO, Sept. 17, 2026 (GLOBE NEWSWIRE) -- Crohn’s and Colitis Canada and AbbVie Canada are proud to announce the 2026 recipients of the AbbVie IBD Scholarship Program. Fifteen students from across ...
RINVOQ is the first and only systemic medication approved in the European Union to treat adult and adolescent patients with non-segmental vitiligo (NSV) who are candidates for sys ...
The Crohn's & Colitis Foundation will host its 59th Annual Gala at the Edison Ballroom, featuring Broadway performances and celebrating 25 years of ...
Detailed price information for Takeda Pharmaceutical Ltd ADR (TAK-N) from The Globe and Mail including charting and trades.
Merck has revealed detailed data for tulisokibart from a mid-stage trial in hidradenitis suppurativa that analysts say could ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results